Live Breaking News & Updates on Cardiovascular Division At Brigham

Stay updated with breaking news from Cardiovascular division at brigham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban. ....

Massachusetts , United-states , Philadelphia , Pennsylvania , Boston , American , Cardiovascular-division-at-brigham , American-heart-association , Harvard-medical-school , Data-monitoring-committee , Cardiovascular-division

TIMI Study: Novel Anti-Clot Drug Cuts Bleeding in A-Fib Patients

TIMI Study: Novel Anti-Clot Drug Cuts Bleeding in A-Fib Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Philadelphia , Pennsylvania , United-states , American , Daiichi-sankyo , Novartis , Study-group , Cardiovascular-division-at-brigham , Astrazeneca , Bristol-myers-squibb , Pfizer , Data-monitoring-committee

Dr Christopher Cannon on Dual SGLT1/2 Inhibitors

Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a study of sotagliflozin for patients with acute heart failure. ....

Harvard-medical-school , Cardiovascular-division-at-brigham , Cardiovascular-division , Sotagliflozin , Ual-sodium-glucose-cotransporter-1-and-2-inhibitor , Sglt1-2 ,